ArticleGenes and immunity2025
Novel modulation of T effector memory cells-expressing CD45RA by prednisone in inoperable advanced type B thymoma patients.
Article in Genes and immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Efficacy and safety of high-dose prednisone for patients with advanced thymoma: a retrospective study.Journal of thoracic disease · 2026Article
- Neoadjuvant Glucocorticoids Facilitate Resection in Advanced B-Type Thymomas: A Propensity-Matched Analysis of Surgical and Survival Outcomes.Thoracic cancer · 2026Article
- Case report: Thymoma-associated GAD65 autoimmunity: a unifying mechanism for multi-organ injury involving nervous, endocrine, and renal systems.Frontiers in immunology · 2026Article
- Surgical Expert Consensus on Clinical Management of Advanced Thymoma and Thymic Carcinoma: A Beijing-Tianjin-Hebei Collaborative Initiative.Thoracic cancer · 2025Article
- Methylprednisolone pulse versus docetaxel in recurrent thymoma with myasthenia gravis.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the covert onset of thymoma, nearly 30% of patients are diagnosed at stage III or IV, losing the opportunity for surgical treatment. We have initiated the application of prednisone in treating refractory thymoma and explored biomarkers to identify potential cases that might benefit from prednisone treatment. In a study involving 96 patients with thymoma, we confirmed a significant tumor shrinkage with prednisone acetate treatment. A reduced diameter ratio indicated that type B1 and B2 thymomas exhibited the most obvious response to prednisone acetate, especially type B2 thymoma. However, the reduced diameter ratio was < 30% in type A, AB, and B3 thymomas. Immunofluorescence and flow cytometry of tumor tissues indicated that TEMRA (T Effector Memory-Expressing CD45RA) cells primarily exist in type B thymoma. However, the percentage of interleukin-8 + TEMRA cells decreased only in B1 and B2 thymoma tissues after prednisone acetate treatment. These findings are particularly significant for patients with type B thymoma with stage III or IV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.